Moderna CEO: Health Care Workers Could Get Vaccine by Fall

Josh Nathan-Kazis Biotech BNTX GS MRNA Goldman Sachs BioNtech Moderna National Institute of Allergy and Infectious Diseases Pharmaceuticals Vaccines Health Care/Life Sciences Specialized Drugs/Medications Stéphane Bancel Financial Performance New Products/Services Research/Development Management Corporate/Industrial News Products/Services Senior Level Management New Product/Service Testing Political/General News Respiratory Tract Diseases Health Immunizations Medical Conditions Outbreaks/Epidemics Novel Coronaviruses Infectious Diseases Medical Treatments/Procedures Commodity/Financial Market News Content Types Factiva Filters C&E Exclusion Filter C&E Industry News Filter GS I/DRG M/HCR N/CNW N/COF N/DJN N/GEN N/HLT N/MKT N/MNT N/NWS N/PDT N/PFM N/RND N/WER Barrons.com Barrons Blogs Wires DJIA Dow JOnes Industrial Average S&P 500 SPX CODES_REVIEWED Biotech Companies Coronavirus Health author Josh Nathan-Kazis author|Josh Nathan-Kazis topicid 8583 name Josh Nathan-Kazis extractedtext Josh Nathan-Kazis rank 1 codetype author code josh_nathan_kazis nameformat surname_first author Josh Nathan-Kazis id Josh Nathan-Kazis barrons_display_subject BARBIO barrons_display_subject|BARBIO codetype BARRONS_DISPLAY_SUBJECT canbedisplaysubject true value BARBIO source MANUAL status modified name Biotech code BARBIO co gldmns co|gldmns country US symbol GS displayname Goldman Sachs Group why occur extractedtext Goldman Sachs source FACTIVA seoname goldman_sachs_group countrycode US relevancerange low chartingsymbol STOCK/US/XNYS/GS fcode gldmns fullextractedtext Goldman Sachs ticker GS confidence 100 subcat com relevance 25 significance prominent name Goldman Sachs confidencerange high exchange NYSE exchangeisocode XNYS codetype co code gldmns status modified onlinesignificance prominent co nilgyd co|nilgyd fullextractedtext National Institute of Allergy and Infectious Diseases displayname National Institute of Allergy and Infectious Diseases confidence 100 why occur extractedtext National Institute of Allergy and Infectious Diseases source FACTIVA subcat org relevance 16 significance passing name National Institute of Allergy and Infectious Diseases confidencerange high relevancerange low fcode nilgyd codetype co code nilgyd onlinesignificance passing-mention co MDRTHU co|MDRTHU symbol MRNA country US codetype co displayname Moderna extractedtext Moderna source MANUAL code mrna name Moderna significance prominent exchange U.S.: Nasdaq exchangeisocode XNAS chartingsymbol STOCK/US/XNAS/MRNA fcode MDRTHU status modified onlinesignificance prominent co HWMLCB co|HWMLCB symbol BNTX country US codetype co displayname BioNTech SE extractedtext BioNtech source MANUAL code bntx name BioNtech significance prominent exchange U.S.: Nasdaq exchangeisocode XNAS chartingsymbol STOCK/US/XNAS/BNTX fcode HWMLCB status modified onlinesignificance prominent company MRNA company|MRNA name Moderna significance PASSING-MENTION company GS company|GS name Goldman Sachs significance PASSING-MENTION company BNTX company|BNTX name BioNtech significance PASSING-MENTION djn GS djn|GS significance passing name GS why occur source FACTIVA fcode GS codetype djn code gs onlinesignificance passing-mention djn I/DRG djn|I/DRG significance prominent name I/DRG why about source FACTIVA fcode I/DRG codetype djn code i_drg onlinesignificance prominent djn M/HCR djn|M/HCR name M/HCR why lineage source FACTIVA fcode M/HCR codetype djn code m_hcr djn N/COF djn|N/COF significance prominent name N/COF why about source FACTIVA fcode N/COF codetype djn code n_cof onlinesignificance prominent djn N/MKT djn|N/MKT significance prominent name N/MKT why about source FACTIVA fcode N/MKT codetype djn code n_mkt onlinesignificance prominent djn N/NWS djn|N/NWS significance prominent name N/NWS why about source FACTIVA fcode N/NWS codetype djn code n_nws onlinesignificance prominent djn N/PFM djn|N/PFM significance prominent name N/PFM why about source FACTIVA fcode N/PFM codetype djn code n_pfm onlinesignificance prominent djn N/HLT djn|N/HLT significance prominent name N/HLT why about source FACTIVA fcode N/HLT codetype djn code n_hlt onlinesignificance prominent djn N/PDT djn|N/PDT name N/PDT why lineage source FACTIVA fcode N/PDT codetype djn code n_pdt djn N/RND djn|N/RND name N/RND why lineage source FACTIVA fcode N/RND codetype djn code n_rnd djn N/MNT djn|N/MNT name N/MNT why lineage source FACTIVA fcode N/MNT codetype djn code n_mnt djn N/CNW djn|N/CNW name N/CNW why lineage source FACTIVA fcode N/CNW codetype djn code n_cnw djn N/GEN djn|N/GEN name N/GEN why lineage source FACTIVA fcode N/GEN codetype djn code n_gen djn N/DJN djn|N/DJN codetype djn value N/DJN source DJN-CONTROL status modified inactivebydefault true name N/DJN code n_djn djn N/WER djn|N/WER codetype djn value N/WER source DJN-CONTROL status modified inactivebydefault true name N/WER code n_wer first_publish_headline Moderna CEO Says Health Care Workers Could Get a Covid-19 Vaccine by Fall first_publish_headline|Moderna CEO Says Health Care Workers Could Get a Covid-19 Vaccine by Fall flow NWREGULAR flow|NWREGULAR codetype FLOW value NWREGULAR source MANUAL status modified name Wires code NWREGULAR flow Barrons.com flow|Barrons.com codetype FLOW value Barrons.com source MANUAL status modified name Barrons.com code online name Online title Product code Barrons.com flow Barrons Blogs flow|Barrons Blogs codetype FLOW value Barrons Blogs title Product source MANUAL status modified name Barrons Blogs code Barrons_Blogs headline Moderna CEO Says Health Care Workers Could Get a Covid-19 Vaccine by Fall headline|Moderna CEO Says Health Care Workers Could Get a Covid-19 Vaccine by Fall in i2572 in|i2572 significance prominent name Vaccines why about source FACTIVA fcode i2572 codetype in code i2572 onlinesignificance prominent in i257 in|i257 significance prominent name Pharmaceuticals why about source FACTIVA fcode i257 codetype in code i257 onlinesignificance prominent in i951 in|i951 name Health Care/Life Sciences why lineage source FACTIVA fcode i951 codetype in code i951 in idrugty in|idrugty name Specialized Drugs/Medications why lineage source FACTIVA fcode idrugty codetype in code idrugty index S&P 500 index|S&P 500 symbol SPX country US codetype index displayname S&P 500 Index extractedtext S&P 500 source MANUAL code spx name S&P 500 significance prominent exchange S&P US exchangeisocode S&P US chartingsymbol INDEX/US/S&P US/SPX status modified onlinesignificance prominent index Dow JOnes Industrial Average index|Dow JOnes Industrial Average symbol DJIA country US codetype index displayname Dow Jones Industrial Average extractedtext Dow JOnes Industrial Average source MANUAL code djia name Dow JOnes Industrial Average significance prominent exchange Dow Jones Global exchangeisocode DOW JONES GLOBAL chartingsymbol INDEX/US/DOW JONES GLOBAL/DJIA status modified onlinesignificance prominent media media-2 media|media-2 responsive layout wrap softcrop Horizontal imphotoid im-167938 location https://images.barrons.com/im-167938/?size=1.5 media media-1 media|media-1 softcrop Horizontal imphotoid im-167938 location https://images.barrons.com/im-167938/?size=1.5 ns cslmc ns|cslmc significance prominent name Senior Level Management why about source FACTIVA fcode cslmc codetype ns code cslmc onlinesignificance prominent ns mcat ns|mcat significance prominent name Commodity/Financial Market News why about source FACTIVA fcode mcat codetype ns code mcat onlinesignificance prominent ns gsars ns|gsars significance prominent name Novel Coronaviruses why about source FACTIVA fcode gsars codetype ns code gsars onlinesignificance prominent ns gout ns|gout significance prominent name Outbreaks/Epidemics why about source FACTIVA fcode gout codetype ns code gout onlinesignificance prominent ns c15 ns|c15 significance prominent name Financial Performance why about source FACTIVA fcode c15 codetype ns code c15 onlinesignificance prominent ns ghea ns|ghea significance prominent name Health why about source FACTIVA fcode ghea codetype ns code ghea onlinesignificance prominent ns gimmu ns|gimmu significance prominent name Immunizations why about source FACTIVA fcode gimmu codetype ns code gimmu onlinesignificance prominent ns ctrial ns|ctrial significance prominent name New Product/Service Testing why about source FACTIVA fcode ctrial codetype ns code ctrial onlinesignificance prominent ns c22 ns|c22 name New Products/Services why lineage source FACTIVA fcode c22 codetype ns code c22 ns c23 ns|c23 name Research/Development why lineage source FACTIVA fcode c23 codetype ns code c23 ns c41 ns|c41 name Management why lineage source FACTIVA fcode c41 codetype ns code c41 ns ccat ns|ccat name Corporate/Industrial News why lineage source FACTIVA fcode ccat codetype ns code ccat ns cexpro ns|cexpro name Products/Services why lineage source FACTIVA fcode cexpro codetype ns code cexpro ns gcat ns|gcat name Political/General News why lineage source FACTIVA fcode gcat codetype ns code gcat ns gcold ns|gcold name Respiratory Tract Diseases why lineage source FACTIVA fcode gcold codetype ns code gcold ns gmed ns|gmed name Medical Conditions why lineage source FACTIVA fcode gmed codetype ns code gmed ns gspox ns|gspox name Infectious Diseases why lineage source FACTIVA fcode gspox codetype ns code gspox ns gtrea ns|gtrea name Medical Treatments/Procedures why lineage source FACTIVA fcode gtrea codetype ns code gtrea ns ncat ns|ncat name Content Types why lineage source FACTIVA internalsymbol true fcode ncat codetype ns code ncat ns nfact ns|nfact name Factiva Filters why lineage source FACTIVA internalsymbol true fcode nfact codetype ns code nfact ns nfce ns|nfce name C&E Exclusion Filter why lineage source FACTIVA internalsymbol true fcode nfce codetype ns code nfce ns nfcpin ns|nfcpin name C&E Industry News Filter why lineage source FACTIVA internalsymbol true fcode nfcpin codetype ns code nfcpin nwchain SB510073332613690248088045862793533565067101 nwchain|SB510073332613690248088045862793533565067101 pe 12629775 pe|12629775 lastname Bancel displayname Bancel, Stéphane confidence 92 why occur extractedtext Stéphane Bancel source FACTIVA relevance 75 significance passing firstname Stéphane name Stéphane Bancel confidencerange high relevancerange medium fcode 12629775 codetype pe code 12629775 nameformat surname_first onlinesignificance passing-mention relay SYND relay|SYND name Syndication source EXPANDER value SYND codetype RELAY code synd status modified statistic CODES_REVIEWED statistic|CODES_REVIEWED name CODES_REVIEWED value CODES_REVIEWED codetype STATISTIC code CODES_REVIEWED subject BARCOMP subject|BARCOMP ruleid BARCOMP codetype SUBJECT value BARCOMP canbedisplaysubject true name Companies title Companies status modified code BARCOMP subject BARCORONA subject|BARCORONA ruleid BARCORONA codetype SUBJECT value BARCORONA canbedisplaysubject true name Coronavirus title Coronavirus status modified code BARCORONA subject BARHEALTH subject|BARHEALTH ruleid BARHEALTH codetype SUBJECT value BARHEALTH canbedisplaysubject true name Health title Health status modified code BARHEALTH subject BARBIO subject|BARBIO ruleid BARBIO codetype SUBJECT value BARBIO canbedisplaysubject true name Biotech title Biotech status modified code BARBIO wordcount 378 wordcount|378 id facebook id|facebook news_tab_url https://www.barrons.com/articles/health-care-workers-could-get-a-coronavirus-vaccine-by-fall-moderna-ceo-says-51584982422 Photograph by THIBAULT SAVARY/AFP via Getty Images Moderna CEO Says Health Care Workers Could Get a Covid-19 Vaccine by Fall Moderna CEO Says Health Care Workers Could Get a Covid-19 Vaccine by Fall Health Care Workers Could Get a Coronavirus Vaccine by Fall: Moderna CEO Says

CEO Stéphane Bancel also said Moderna was scaling up its manufacturing capacity so it will be able to make millions of doses of the coronavirus vaccine a month.

Moderna CEO: Health Care Workers Could Get Vaccine by Fall

CEO Stéphane Bancel also said the company was scaling up its manufacturing capacity so it will be able to make millions of doses of the vaccine a month.

https://www.barrons.com/articles/moderna-stock-jumps-after-it-doses-first-patient-in-coronavirus-vaccine-trial-51584380924 https://investors.modernatx.com/node/8501/html https://www.barrons.com/articles/biontech-stock-coming-coronavirus-vaccine-trials-51584368813 mailto:josh.nathan-kazis@barrons.com Moderna CEO Says Health Care Workers Could Get a Covid-19 Vaccine by Fall By Josh Nathan-Kazis Photograph by THIBAULT SAVARY/AFP via Getty Images

The biotech firm Moderna, which is testing a vaccine to prevent Covid-19, now says it’s “possible” that a vaccine could be made available to health care workers this fall.

Moderna (ticker: MRNA) is developing the vaccine with the National Institute of Allergy and Infectious Diseases, which is currently running a Phase 1 study of the vaccine in 45 healthy adults. Moderna announced March 16 that the first patient in the Phase 1 study had been dosed, and that it was preparing doses for a Phase 2 trial.

In a Securities and Exchange Commission filing on Monday, Moderna disclosed that its CEO, Stéphane Bancel, told Goldman Sachs (GS) representatives on Friday that while no vaccine will be commercially available for Covid-19 for 12 to 18 months, a vaccine could be made available to certain people, including medical professionals, in the fall of this year on an emergency basis.

Bancel also told Goldman Sachs that Moderna was scaling up its manufacturing capacity so it will be able to make millions of doses of the vaccine a month.

Moderna is one of a handful of companies developing vaccines to prevent Covid-19 using messenger RNA technology. Its program was among the earliest to receive widespread attention. Shares of Moderna are up 41.8% so far this year, though they had fallen 1.7% midday Monday amid a broader selloff that sent the S&P 500 down 3.3% and the Dow Jones Industrial Average down 3.4%.

Other companies developing mRNA-based Covid-19 vaccines include BioNtech (BNTX) and CureVac, a privately held German firm.

Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.